| Quarter | Revenue | YoY | Net Income | EPS (Diluted) | YoY | Gross Margin | Op. Margin |
|---|---|---|---|---|---|---|---|
| Q1 2026 Mar 2026 | $585.5M | -1.4% | $-40.2M | $-0.06 | +60.0% | 67.2% | 5.1% |
| Q4 2025 Dec 2025 | $617.0M | — | $3.1M | $0.00 | — | 66.8% | 9.4% |
| Q3 2025 Sep 2025 | $623.1M | — | $-28.3M | $-0.04 | — | 65.0% | 6.5% |
| Q2 2025 Jun 2025 | $621.4M | — | $-72.0M | $-0.11 | — | 67.2% | 7.9% |
| Q1 2025 Mar 2025 | $593.7M | — | $-103.9M | $-0.15 | — | 65.1% | 4.1% |
Data from Yahoo Finance. YoY compares the same quarter of the prior fiscal year.
| Metric | Current | Forward |
|---|---|---|
| EPS | — | $0.78 |
| Revenue | — | $2.45 B |
| P/E | — | 3.16 |
| Dividend | — | — |
| Profit Margin | -5.62% | — |
| PEG Ratio | 0.18 | — |
| Beta (5Y) | 1.41 | — |
Clarivate Earnings exceed expectations, stock soars 32.4% – what’s behind the numbers, outlook, and Life Sciences sale.